April 2025 — Responding to the global demand for advanced drug delivery systems, Litchlab is proud to announce the launch of its Hydrogel Drug Delivery Technology Platform and CDMO Services, offering end-to-end support from formulation development and process scale-up to GMP manufacturing and regulatory filing. The new platform empowers pharmaceutical innovators to accelerate clinical translation of next-generation therapies.
As the global CDMO industry shifts toward high-tech, high-value-added solutions, hydrogels have emerged as a promising material with excellent moisture retention, biocompatibility, and controlled release capabilities. Hydrogels are gaining momentum in areas such as complex drug delivery, implant systems, regenerative medicine, and mRNA vaccines. Litchlab is taking a proactive step with an industrial-ready hydrogel platform tailored to meet this growing demand.
✅ Versatile Hydrogel System Development
Natural Polymers: Alginate, Gelatin, Hyaluronic Acid, Chitosan
Synthetic Polymers: PEG, PLGA-PEG, PVA, Hydrogel-forming Acrylates
Composite Hydrogels: Smart-response systems (temperature, pH, enzymatic)
✅ Multiple Delivery Formats
Injectable in situ forming gels
Implantable hydrogel matrices
Micro/nano hydrogel particles (for SC injection, ocular/dermal delivery)
Combination delivery with liposomes, nanoparticles, etc.
✅ Broad Drug Compatibility
Small molecules, peptides, proteins, antibodies, vaccines, siRNA/mRNA, extracellular vesicles (EVs)
Sterile formulation & aseptic filling development
Crosslinking mechanism control (chemical/physical/enzymatic)
Customized gelation, rheology, and release profiles
Seamless scale-up from lab to clinical-grade manufacturing
Supports multiple dosage forms: sterile liquids, lyophilized powders, injectables, gels
Comprehensive gel strength, swelling, and drug release testing
Cytocompatibility, degradation safety, and toxicology studies
ICH-compliant stability assessments
Regulatory dossier preparation for FDA, EMA, NMPA (IND, IMPD, etc.)
| Field | Representative Projects |
|---|---|
| Oncology | In situ gel for post-surgical recurrence prevention |
| Pain Management | Long-acting local anesthetic delivery system |
| Regenerative Medicine | Growth factor scaffold / cell-encapsulated hydrogels |
| Vaccine Delivery | Hydrogel adjuvant platform for mRNA vaccines |
| Ocular/Dermal Use | Sustained-release eye drops / wound-healing gel formulations |
✔️ Comprehensive hydrogel drug delivery CDMO service platform
✔️ Advanced crosslinking design and release control expertise
✔️ Seamless integration with lipid nanoparticles, microspheres, etc.
✔️ Full chain capabilities from R&D to GMP clinical production
✔️ Complete IND/NDA regulatory support
“Hydrogel delivery systems are a critical enabler for personalized medicine and long-acting therapeutics,” said Dr. Liu Tao, Director of Operations at Litchlab. “We’re committed to being the trusted, high-quality, and responsive hydrogel development partner for innovators worldwide.”
📞 Partner with us to shape the future of hydrogel drug delivery.
🔗 Learn more: www.litchlab.com
📧 Contact: RD2@litchlab.com
